- [Resource Hub](/) - [Resource](/?resource-type=poster#library) - Sequential same slide multiplex immunofluorescence and H&E staining for combined phenotypic and morphologic characterization of formalin-fixed paraffin-embedded tissue sections # Sequential same slide multiplex immunofluorescence and H&E staining for combined phenotypic and morphologic characterization of formalin-fixed paraffin-embedded tissue sections Multiplex immunofluorescence and H&E normally run on two different serial sections, which no longer contain the same cells and are not always obtainable when tissue is limited; this AACR 2020 poster stains and images both on a single slide, in sequence, on one instrument. Presented by RareCyte, Ultivue, and Indica Labs. Read or download to see: - Multiplex immunofluorescence and H&E ran in sequence on one physical slide, not on two serial sections. In FFPE samples from 3 serial sections of tonsil and primary colon and lung tumor biopsies, CD8, CD68, PD-L1 and pan-Cytokeratin were stained with Ultivue’s UltiMapper I/O PD-L1 kit on a Leica Biosystems BOND RX, imaged in five spectrally distinct fluorescence channels (DAPI, FITC, TRITC, Cy5, Cy7) on the RareCyte CyteFinder II HT, then de-coverslipped, stained with H&E and re-imaged in brightfield on that same instrument — so the morphology and the protein phenotypes describe the identical cells. - A classifier trained on the H&E image separated tumor from stroma as well as one trained on the fluorescent cytokeratin and DAPI signal. Across the colon and lung sections, HALO AI segmentation gave per-region cell counts the authors describe as comparable, which is what leads them to conclude that a tumor-specific biomarker could be dropped from the fluorescence panel when the H&E carries the tissue architecture. Read that as their qualitative call rather than a measured equivalence: Figure 2 plots the counts on a log axis and reports no statistical test, and Lung 5 had to borrow Lung 6’s tumor/stroma segmentation after the tissue was damaged during de-coverslipping. - Cell phenotypes were counted inside the tissue regions the H&E defined, not across the section as a whole. HALO Highplex FL scored CD8+ cytotoxic T-cells, CD68+ macrophages, CD68+/PD-L1+ immuno-suppressive macrophages, pan-CK+ tumor cells and pan-CK+/PD-L1+ immune-evading tumor cells within the tumor and stromal regions, and the authors report the UltiMapper I/O PD-L1 kit stained reproducibly across the serial sections. RareCyte instruments are for research use; H&E is a clinical stain, but this workflow makes no diagnostic claim. [Download poster](https://cdn.sanity.io/files/s3p6uqps/production/bdb0826b695fd28362b87aba2f6918fa7f25becf.pdf) Your browser doesn’t support embedded PDFs. [Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/bdb0826b695fd28362b87aba2f6918fa7f25becf.pdf) to view it. [Back to all resources](/#library) ## Related resources [Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) CyteFinder SelectScience ### Measuring versus reading – transforming the field of quantitative pathology [Read Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) [Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyyz/455452/220141/TS20_103.pdf) CyteFinder ### CyteFinder II HT [View Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyyz/455452/220141/TS20_103.pdf) [Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) CyteFinder ### CyteFinder II [View Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026 ### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes. [View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026 ### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research [Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://doi.org/10.1038/s41587-026-03099-z) CyteFinder Nature Biotechnology 2026 ### mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression [View Publication](https://doi.org/10.1038/s41587-026-03099-z) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) CyteFinder Cancer Immunology Research 2026 ### Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) [Publication](https://doi.org/10.1097/pai.0000000000001311) CyteFinder Applied Immunohistochemistry & Molecular Morphology 2026 ### Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score [View Publication](https://doi.org/10.1097/pai.0000000000001311) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026 ### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026 ### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma [View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026 ### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244) CyteFinder Clinical Cancer Research 2025 ### Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma [View Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244)